BridgeBio gains after settlement in Pfizer Vyndamax patent dispute
BridgeBio Pharma, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $65.36
-3.2% in 7d after detection
Post-detection moves
1h
—
1d
+1.8%
3d
-1.6%
7d
-3.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS